GT
KBIO

Glenmede Trust’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Glenmede Trust’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,088
Closed -$13K – 2960
2015
Q3 		$13K Sell
7,088
-2
-0% -$5 ﹤0.01% 2049
2015
Q2 		$27K Hold
7,090
– – ﹤0.01% 1816
2015
Q1 		$27K Hold
7,090
– – ﹤0.01% 1861
2014
Q4 		$98K Buy
+7,090
New +$101K ﹤0.01% 1541

Other funds holding KBIO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Glenmede Trust's KBIO Position: Q4 2015 in Review

Glenmede Trust sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2015, closing a stake of 7,088 shares — an estimated $13K sold.

Glenmede Trust first reported a position in KBIO in Q4 2014 and held it in 4 quarters. The position peaked at $98K in Q4 2014. 17 funds tracked by Wall St. Rank hold KBIO as of Q4 2015.

  • Glenmede Trust reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2015 after selling out during the quarter.
  • Glenmede Trust sold 7,088 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2015, an estimated $13K.
  • Glenmede Trust first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q4 2014 and held it in 4 quarters.
  • Glenmede Trust's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $98K in Q4 2014.
  • 17 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2015.

Based on Glenmede Trust's 13F filing for Q4 2015, filed 11 Feb 2016.